Biologics Industry Analysis and Forecast
The vaccines segment within the Biologics Market is set to expand from USD 90 Billion in 2024 to USD 140 Billion by 2035, driven by the rising need for infectious disease prevention and immunization programs worldwide. Advances in mRNA technology, as demonstrated during the COVID-19 pandemic, have revolutionized vaccine development timelines. Governments and organizations are investing in robust vaccination infrastructure, especially in developing countries. North America leads due to strong production capabilities and immunization policies, while Asia-Pacific shows rapid growth fueled by population size and emerging biotech hubs. Innovations such as combination vaccines, universal influenza vaccines, and cancer immunization strategies are shaping the segment’s future. Key industry players like Pfizer, Sanofi, and GSK are enhancing production capacity and diversifying vaccine portfolios. The global push for pandemic preparedness will keep vaccines central to biologics market expansion over the next decade.